📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - auf Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Yuman Fong

From EverybodyWiki Bios & Wiki






Yuman Fong
Born2 November 1959 (age 60)
🎓 Alma materLowell High School

Brown University

Cornell University Medical College
💼 Occupation
Known forLiver and Pancreatic Surgery

Surgical Robotics

Gene Therapy

Yuman Fong (born November 2, 1959) is an American surgeon and scientist. He holds the Sangiacomo Chair in surgical oncology and is chairman of the department of surgery at the City of Hope Cancer Center. Fong is best known clinically for his extensive work in the field of hepatobiliary surgery. His work helped establish hepatic resection of colorectal metastases as a safe, effective, and potentially curative option even at stage IV.[1] His most recent work has been to advance the use of ablative and robotic surgery for cancer.[2] He is editor of the Springer textbook on Image-guided Therapies, and The SAGES Atlas in Robotic Surgery.[3] For his clinical work, he was awarded the Layton F. Rikkers Master Clinician Award from the Society for Surgery of the Alimentary Tract.[4]

Fong has assisted in the design and deployment of many novel surgical tools and gene surgery tools [clarification needed]. His group is now working on cell culture and cell-based production of biologics with the goal of making gene therapies, cell therapies, and vaccines affordable and accessible to all.[5] His work in medical engineering has led to his election to the American Institute of Medical and Biologic Engineering.[6]

Fong’s early research was in immune activation during cancer or infection. He was part of the group that discovered tumor necrosis factor and helped established the field of innate immunity.[7] His laboratory focus over the last 15 years has been in the field of gene therapy. His group was the first to administer recombinant viruses into the human blood stream as a cancer treatment.[8] His leadership in this field earned him the honor of serving as the Chair of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health.[9]. He is the founding Editor-in-Chief of Molecular Therapy Oncolytics (Cell Press, journal of ASGCT)[10]

He has co-authored over 1000 articles and 17 textbooks. PLOS Biology, recognized Fong in 2019 as one of the most-cited researchers in the world.[11] Fong was also ranked by Google Scholar as one of the top 1000 most-cited researchers.[12] He has the number-one-cited paper in the history of the American Surgical Association.[13]

Early life

Fong was born on November 2, 1959 in Kowloon. His father Kui Fong was a civil engineer; his mother, Wai Yuet (Tang) Fong, was a seamstress. The Lectureship at the Society of Asian Academic Surgeons honoring parents who have contributed to the success of academic surgeons is named the Kui and Wai Fong Lectureship.[14]

The family emigrated to San Francisco California in 1969.

Education

In 1977, Fong was admitted to and matriculated in the 7-year combined BA-MD program at Brown University. In 1982, he transferred to Cornell University Medical College. This was followed by surgical training at the New York Hospital/Cornell Medical Center under G. Thomas Shires, a research fellowship under Stephen Lowry, and a surgical oncology fellowship Murray Brennan at the Memorial Sloan-Kettering Cancer Center.

Academic career

Fong was appointed an assistant professor to the faculty at Memorial Sloan-Kettering Cancer Center in 1993 with an academic appointment at The Weill Cornell Medical Center. In 2000 he was promoted from assistant to full professor with tenure at Cornell University. For over twenty years, he was an attending surgeon at the Memorial Sloan-Kettering Cancer Center (MSKCC), where he held the Murray F. Brennan Chair in Surgery.

In 2014, he left New York to return to California. He was appointed Chairman of the Department of Surgery at the City of Hope Medical Center[15]. There he held the Sangiacomo Family Chair in Surgical Oncology, named for Angelo and Yvonne Sangiacomo[16]

Scientific work

Fong was a post-doctoral fellow along with Kevin Tracey in the laboratory of Stephen Lowry. In collaboration with Lyle Moldawer and Anthony Cerami progress was made in uncovering the biology of tumor necrosis factor that had just been discovered and the gene sequenced in the Cerami lab. Their work demonstrated that blockade of tumor necrosis factor can prevent sepsis.[17] They also showed that blocking tumor necrosis factor can shut down the entire cascade of cytokines in sepsis and inflammation.[18] They also demonstrated that individual organs contained pools of immune cells that can be the source of cytokines.[19] These studies laid the foundation for anti-TNF therapies (Remicade, Humira, Cimzia, Simponi) now widely used for inflammatory diseases including arthritis.[citation needed]

Collaboration with Howard Federofff led to invention of a method of rapidly producing cancer vaccines using irradiated tumor cells infected with cytokine secreting herpes vectors[20]. Their work also included the first administration of genetically modified viruses into the bloodstream of humans for cancer[21]. Their work included the first non-invasive imaging of viral replication in vivo[22], and demonstration that oncolytic viruses can be used as diagnostic agents in cancer[23]. Since moving to the City of Hope Medical Center, Fong has collaborated with Nanhai Chen to produce the next generation oncolytic chimeric pox viruses that have an ability to infect and kill almost every tumor type[24]. He has collaborated in producing viruses that can label cancer cells for killing by Car-T cells.[25]

Fong has worked on design and use of a class of AAV gene editing vectors capable of editing with no off-target editing.[26] He is attempting to produce viral vectors and viral vaccines at 10-1000 times more efficient level.[27]

Fong contributed to data that proved that stage 4 metastatic disease to the liver can be cured, and devised a new scoring system (Fong Score) widely used in staging of such hepatic colorectal metastases. Other important contributions in this area include demonstration that liver surgery at high volume centers resulted in improved long-term cancer-related survival,[28] and the first demonstration that systemic chemotherapy is useful as adjuvant after liver resection.[29] More recently, Fong’s group collaborating with Bryan Cleary at the University of California San Diego has highlighted the low level of use of liver resection in California and across the nation. Less than 10% of patients with such disease are offered resection when 40-50% are candidates.[30]

Fong’s work contributed to the demonstration that microwave ablation of liver tumors can be curative[31]. In a collaboration with Serge Evrard (Bordeaux) and Graham Poston (Liverpool, England) they demonstrated that ablations can be combined with resection to extend the number of patients that can be offered potentially curative treatment of liver tumors[32] His group reported the first description of single port laparoscopic hepatectomy[33]. They contributed significant data that robotic resection of liver tumors has superior outcomes[34]. More recently, his group demonstrated that robotic liver surgery can be safely and routinely performed as outpatient surgery[35]

Scientific Service

Fong has been Editor-in-Chief of the American Cancer Society series in Patient Management Problems, the Journal of Interventional Oncology, and Molecular Therapy Oncolytics.[citation needed]

He has served on the Foundation Board of the Society of University Surgeons (SUS), the Board of Trustees of the Society for Surgery of the Alimentary Tract, and the board of directors of the James IV Association of Surgeons. Fong has also served as the treasurer, Vice-president, and president of the International Surgical Group.

He has Chaired the NIH workshop on complementary med (American Society for Parenteral and Enteral Nutrition) 1992; the NIH workshop on Nucleotide Therapies 2012, and The NIH workshop on Gene Therapy, Charting a Future Course 2013. He served as Chairman, Liver Studies Committee for the Commission on Cancer National Cancer Database, 2002-2007. He served as the Chairman, Hepatobiliary Organ Site Committee (1999-2002) and the Upper GI Committee (2002-2004) for the American College of Surgeons Oncology Group. He served as the Chairman, Hepatobiliary Committee for the National Cancer Database 2002-2007. He served as Chair of the Recombinant DNA Advisory Committee (National Institutes of Health) 2011-2013, and on the National DSMB for gene therapy.

He served on the International Advisory Committee of the Princess Chulabhorn Cancer Center in Bangkok, Thailand. He served as the Honorary Overseas Advisor, Surgical Oncology Department of the Cancer Center Welfare Home and Research Institute Kolkata, India.

Honors and awards

  • Stanley Dudrick Research Scholar Prize-American Society for Parenteral and Enteral Nutrition, 1994
  • Boyer Research Award, Memorial Sloan-Kettering Cancer Center, 1996
  • James IV Surgical Traveler, James IV Association of Surgeons, 1999
  • Election, American Society of Clinical Investigation, 2003
  • Election, American Institute of Medical and Biologic Engineering (AIMBE), 2018
  • Layton F. Rikkers Master Clinician Award, Society for Surgery of the Alimentary Tract, 2019

Personal

Fong is married to Nicole Victoria Bergman, a corporate finance attorney. They have three children, the sports shooters Sandra Fong, Abigail Fong, and Daniellla Fong.

Media

An NBC TV documentary production named “My First Time: The Beijing Olympics” documented life in the Fong household as Sandra and Danielle prepared for the Beijing games. It aired on the opening night of the games and won an Emmy for best sports special 2008 [citation needed]. A production entitled “A Day in the Life of Dr. Yuman Fong” won a Telly Award in 2019 [citation needed]

Books

Blumgart LH, Fong Y. Surgery of the liver and biliary tract. Churchill Livingstone: London, CD-ROM ed: 1.1, 1997.

Clavien P, Fong Y, Lyerly K, Venook A. Primary and Secondary Liver Tumors: Current and Emerging Therapies. Blackwell Science Inc.: Malden MA, 1999.

Blumgart LH, Fong Y. Surgery of the liver and biliary tract. W.B. Saunders Co. Ltd.: London, 3rd Edition, 2000.

Blumgart LH, Fong Y, Jarnagin W. Hepatobiliary Cancer. American Cancer Society Atlas of Clinical Oncology. B.C.Decker, Hamilton, 2000.

Moorse M, Clavien P, Fong Y. Malignant Hepatic Neoplasms. Blackwell Science Inc.: Malden MA. 2002.

Clavien P, Sarr M, Fong Y. Atlas of Gastrointestinal and Hepato-Pancreatobiliary Surgery. Springer: Munich, 2007.

Jankowski J, Sampliner R, Kerr D, Fong Y. Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach. Blackwell Publishing: Oxford, 2007.

Dupuy D, Fong Y, McMullen W. Interventional Oncology. Springer, 2013.

Fong Y, Dong D. Hepatobiliary Cancer. People’s Publishing USA, 2014.

Fong Y, Agarwal A. Gallbladder Cancer. 2014.

Fong Y, Giulianotti PC, Lewis J, Groot Koerkamp B. The Modern Operating Room: Changing Role of Imaging and Visualization in Surgery. Springer, 2014.

Fong Y, Kaufmann R, Marchinkowski E, Singh G, Schoelhammer H

  1. ↑ Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (September 1999). "Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases". Annals of Surgery. 230 (3): 309–18, discussion 318-21. doi:10.1097/00000658-199909000-00004. PMC 1420876. PMID 10493478.
  2. ↑ Nota CL, Woo Y, Raoof M, Boerner T, Molenaar IQ, Choi GH, et al. (February 2019). "Robotic Versus Open Minor Liver Resections of the Posterosuperior Segments: A Multinational, Propensity Score-Matched Study". Annals of Surgical Oncology. 26 (2): 583–590. doi:10.1245/s10434-018-6928-1. PMC 7883340 Check |pmc= value (help). PMID 30334196.
  3. ↑ Fong Y, Woo Y, Hyung WJ, Lau C, Strong VE, eds. (2018). The SAGES Atlas of Robotic Surgery. doi:10.1007/978-3-319-91045-1. ISBN 978-3-319-91043-7. Unknown parameter |s2cid= ignored (help) Search this book on
  4. ↑ "Layton F. Rikkers Master Clinician Award Recipients". Society for Surgery of the Alimentary Tract. Retrieved 2021-02-11. Unknown parameter |url-status= ignored (help)
  5. ↑ Cook CA, Boyoglu C, Bugga L, Liu YH, Lu J, Pang KM, et al. (2020-04-28). "A Universal High Density Cell Respirator (HDCR) Bioreactor for Intensified Production of Gene Therapy Vectors". Molecular Therapy. 28 (4): 30–31. ISSN 1525-0016.
  6. ↑ "Yuman Fong Dr. Yuman Fong Inducted into Medical and Biological Engineering Elite - AIMBE". Retrieved 2021-02-11.
  7. ↑ Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. (December 1987). "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia". Nature. 330 (6149): 662–4. Bibcode:1987Natur.330..662T. doi:10.1038/330662a0. PMID 3317066. Unknown parameter |s2cid= ignored (help)
  8. ↑ Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, et al. (December 2006). "Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver". Human Gene Therapy. 17 (12): 1214–24. doi:10.1089/hum.2006.17.1214. PMID 17107303.
  9. ↑ "Committee Members,Meetings and Advisory Reports. 2020". www.facadatabase.gov. Retrieved 2021-02-11. Unknown parameter |url-status= ignored (help)
  10. ↑ Fong Y (2014). "MTO: a new journal for a maturing field". Molecular Therapy Oncolytics. 1: 14001. doi:10.1038/mto.2014.1. PMC 4782936. PMID 27119091.
  11. ↑ Ioannidis JP, Baas J, Klavans R, Boyack KW (August 2019). "A standardized citation metrics author database annotated for scientific field". PLOS Biology. 17 (8): e3000384. doi:10.1371/journal.pbio.3000384. PMC 6699798 Check |pmc= value (help). PMID 31404057. Supplementary data tables
  12. ↑ "Top 1000 Researchers according to the number of Citations in Google Scholar public profiles". dx.doi.org. Retrieved 2021-02-11. Unknown parameter |url-status= ignored (help)
  13. ↑ Landreneau JP, Weaver M, Delaney CP, Aminian A, Dimick JB, Lillemoe KD, Schauer PR (April 2020). "The 100 Most Cited Papers in the History of the American Surgical Association". Annals of Surgery. 271 (4): 663–670. doi:10.1097/SLA.0000000000003633. PMID 31663970. Unknown parameter |s2cid= ignored (help)
  14. ↑ Waters A. "Donor Circle | The Society of Asian Academic Surgeons (SAAS)". Retrieved 2021-02-11.
  15. ↑ "City of Hope Names Yuman Fong, MD, Chair, Department of Surgery - The ASCO Post". ascopost.com. Retrieved 2021-02-11.
  16. ↑ "Angelo Sangiacomo, June 10, 1924-Dec. 8, 2015". www.bizjournals.com. Retrieved 2021-02-11. Unknown parameter |url-status= ignored (help)
  17. ↑ Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. (December 1987). "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia". Nature. 330 (6149): 662–4. Bibcode:1987Natur.330..662T. doi:10.1038/330662a0. PMID 3317066. Unknown parameter |s2cid= ignored (help)
  18. ↑ Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. (November 1989). "Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia". The Journal of Experimental Medicine. 170 (5): 1627–33. doi:10.1084/jem.170.5.1627. PMC 2189514. PMID 2809510.
  19. ↑ Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, et al. (June 1990). "The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans". The Journal of Clinical Investigation. 85 (6): 1896–904. doi:10.1172/jci114651. PMC 296656. PMID 2347917.
  20. ↑ Karpoff HM, D'Angelica M, Blair S, Brownlee MD, Federoff H, Fong Y (February 1997). "Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon". The Journal of Clinical Investigation. 99 (4): 799–804. doi:10.1172/JCI119226. PMC 507865. PMID 9045885.
  21. ↑ Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, et al. (December 2006). "Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver". Human Gene Therapy. 17 (12): 1214–24. doi:10.1089/hum.2006.17.1214. PMID 17107303.
  22. ↑ Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, et al. (July 2001). "Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer". Nature Medicine. 7 (7): 859–63. doi:10.1038/89991. PMID 11433353. Unknown parameter |s2cid= ignored (help)
  23. ↑ Adusumilli PS, Stiles BM, Chan MK, Eisenberg DP, Yu Z, Stanziale SF, et al. (April 2006). "Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery". FASEB Journal. 20 (6): 726–8. doi:10.1096/fj.05-5316fje. PMC 1424670. PMID 16467372.
  24. ↑ O'Leary MP, Choi AH, Kim SI, Chaurasiya S, Lu J, Park AK, et al. (April 2018). "Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose". Journal of Translational Medicine. 16 (1): 110. doi:10.1186/s12967-018-1483-x. PMC 5918769. PMID 29699566.
  25. ↑ Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. (September 2020). "Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors". Science Translational Medicine. 12 (559): eaaz1863. doi:10.1126/scitranslmed.aaz1863. PMID 32878978 Check |pmid= value (help). Unknown parameter |s2cid= ignored (help)
  26. ↑ Smith LJ, Wright J, Clark G, Ul-Hasan T, Jin X, Fong A, et al. (July 2018). "Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing". Proceedings of the National Academy of Sciences of the United States of America. 115 (31): E7379–E7388. doi:10.1073/pnas.1802343115. PMC 6077703. PMID 30018062.
  27. ↑ Cook CA, Liu Y, Lu J, Chen N, Fong Y, Tai YC (January 2017). "Gas perfusable microfabricated membranes for high-density cell culture". 2017 IEEE 30th International Conference on Micro Electro Mechanical Systems (MEMS). IEEE: 472–475. doi:10.1109/memsys.2017.7863445. ISBN 978-1-5090-5078-9. Unknown parameter |s2cid= ignored (help)
  28. ↑ Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF (October 2005). "Long-term survival is superior after resection for cancer in high-volume centers". Annals of Surgery. 242 (4): 540–4, discussion 544-7. doi:10.1097/01.sla.0000184190.20289.4b. PMC 1402350. PMID 16192814.
  29. ↑ Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, et al. (May 2007). "Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents". Journal of the American College of Surgeons. 204 (5): 753–61, discussion 761-3. doi:10.1016/j.jamcollsurg.2006.12.036. PMID 17481478.
  30. ↑ Raoof M, Jutric Z, Haye S, Ituarte PH, Zhao B, Singh G, et al. (September 2020). "Systematic failure to operate on colorectal cancer liver metastases in California". Cancer Medicine. 9 (17): 6256–6267. doi:10.1002/cam4.3316. PMC 7476837 Check |pmc= value (help). PMID 32687265 Check |pmid= value (help).
  31. ↑ Leung U, Kuk D, D'Angelica MI, Kingham TP, Allen PJ, DeMatteo RP, et al. (January 2015). "Long-term outcomes following microwave ablation for liver malignancies". The British Journal of Surgery. 102 (1): 85–91. doi:10.1002/bjs.9649. PMC 4593505. PMID 25296639.
  32. ↑ Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, et al. (2014-12-08). "Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases". PLOS ONE. 9 (12): e114404. Bibcode:2014PLoSO...9k4404E. doi:10.1371/journal.pone.0114404. PMC 4259316. PMID 25485541.
  33. ↑ Gaujoux S, Kingham TP, Jarnagin WR, D'Angelica MI, Allen PJ, Fong Y (May 2011). "Single-incision laparoscopic liver resection". Surgical Endoscopy. 25 (5): 1489–94. doi:10.1007/s00464-010-1419-x. PMID 20976489. Unknown parameter |s2cid= ignored (help)
  34. ↑ Kingham TP, Leung U, Kuk D, Gönen M, D'Angelica MI, Allen PJ, et al. (June 2016). "Robotic Liver Resection: A Case-Matched Comparison". World Journal of Surgery. 40 (6): 1422–8. doi:10.1007/s00268-016-3446-9. PMC 4870111. PMID 26913732.
  35. ↑ Melstrom LG, Warner SG, Woo Y, Sun V, Lee B, Singh G, Fong Y (April 2018). "Selecting incision-dominant cases for robotic liver resection: towards outpatient hepatectomy with rapid recovery". Hepatobiliary Surgery and Nutrition. 7 (2): 77–84. doi:10.21037/hbsn.2017.05.05. PMC 5934136. PMID 29744334.

Retrieved from "https://en.everybodywiki.com/index.php?title=Yuman_Fong&oldid=5190389"
License CC BY-SA 3.0
Powered by MediaWiki